Novartis Back In AMD Game With ‘Potential Blockbuster’ Brolucizumab
Novartis says nAMD eye treatment brolucizumab showed further advantages over Eylea in two Phase III studies, reinforcing plans to file in late 2018 for a commercial launch in 2019.
You may also be interested in...
Shares in Eylea-maker Regeneron slid after FDA approved Novartis's competing VEGF inhibitor for treating AMD, but some observers said investors had overreacted.
Novartis used a priority review voucher for brolucizumab, positioning the eye drug for a US launch in late 2019 if the FDA review goes smoothly.
Allergan has been developing abicipar to provide less-frequent dosing in neovascular AMD, but despite success in reducing intraocular inflammation with a new formulation, the injectable still doesn’t match the safety of entrenched competitors.